Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine (commonly known as Tdap) is a combination immunization used to protect against three serious bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough). The "reduced" designation refers to the lower amount of diphtheria and pertussis antigens compared to pediatric formulations. The mechanism of action involves stimulating the immune system to produce antibodies against the toxins produced by *Clostridium tetani* (tetanus), *Corynebacterium diphtheriae* (diphtheria), and *Bordetella pertussis* (pertussis). This provides active immunity by priming the immune system for rapid response upon exposure. Tdap is primarily indicated for booster immunization in adolescents and adults who have previously completed a primary DTaP series in childhood. It is also recommended during pregnancy to protect newborns from pertussis[1][3][4][7].
- Brand names
- BoostrixAdacel
- Other names
- Tdap vaccinetetanus, diphtheria, and acellular pertussis vaccine (Tdap)adult-type tetanus, diphtheria, and acellular pertussis vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine.